Confluence Investment Management LLC Lowers Stake in Enovis Corporation $ENOV

Confluence Investment Management LLC reduced its position in Enovis Corporation (NYSE:ENOV) by 38.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,116 shares of the company’s stock after selling 26,096 shares during the quarter. Confluence Investment Management LLC owned approximately 0.07% of Enovis worth $1,095,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of ENOV. Farther Finance Advisors LLC lifted its position in shares of Enovis by 42.8% in the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock valued at $37,000 after acquiring an additional 367 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares in the last quarter. Elevation Point Wealth Partners LLC purchased a new stake in shares of Enovis during the second quarter worth about $46,000. SJS Investment Consulting Inc. raised its stake in Enovis by 30,340.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock valued at $46,000 after purchasing an additional 1,517 shares during the period. Finally, Nisa Investment Advisors LLC raised its stake in Enovis by 235.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,703 shares of the company’s stock valued at $52,000 after purchasing an additional 1,195 shares during the period. 98.45% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ENOV. Zacks Research upgraded Enovis from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 4th. Canaccord Genuity Group reduced their price objective on shares of Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday, December 17th. UBS Group restated a “buy” rating and set a $50.00 target price on shares of Enovis in a research report on Monday, January 5th. Evercore reaffirmed an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. Finally, Needham & Company LLC lifted their price target on shares of Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $47.43.

Enovis Stock Down 3.7%

Shares of NYSE ENOV opened at $21.74 on Friday. Enovis Corporation has a 52-week low of $21.00 and a 52-week high of $40.69. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of -1.05 and a beta of 1.46. The stock has a 50 day moving average price of $23.26 and a 200 day moving average price of $27.54. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.02.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.95 EPS for the quarter, topping the consensus estimate of $0.81 by $0.14. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The company had revenue of $575.76 million for the quarter, compared to the consensus estimate of $584.30 million. During the same period last year, the business posted $0.98 EPS. Enovis’s quarterly revenue was up 2.6% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts expect that Enovis Corporation will post 2.79 earnings per share for the current year.

Insider Activity at Enovis

In other Enovis news, insider Oliver Engert purchased 1,000 shares of the stock in a transaction dated Friday, February 27th. The stock was purchased at an average price of $25.50 per share, with a total value of $25,500.00. Following the transaction, the insider owned 43,640 shares of the company’s stock, valued at approximately $1,112,820. This trade represents a 2.35% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders have bought 5,000 shares of company stock valued at $121,983. Insiders own 2.70% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.